Calcium goes nuclear by Wells, William A.
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Calcium goes nuclear
 
fine reticulum that pokes its fingers across the 
nucleus is capable of storing and releasing calcium, 
according to Wihelma Echevarría, Michael Nathanson 
(Yale University, New Haven, CT), and colleagues. The 
physiological activators of the compartment remain 
obscure, but they could potentially induce localized 
signaling in the nucleus.
Intranuclear extensions of the ER have been described 
previously, but the Yale group is the first to show that the 
compartment both contains and can release calcium. 
Localized photorelease of inositol 1,4,5-trisphosphate 
(InsP
 
3
 
) in the nucleus resulted in a gradient of calcium 
A
Nuclear calcium transients 
send PKC to the nuclear 
envelope (top right) rather 
than the plasma mem-
brane (bottom right).
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that spread from the site of photorelease across the nucleus. The effects of nuclear 
calcium release were distinct from those of cytosolic calcium release: nuclear calcium 
caused translocation of a labeled protein kinase C (PKC) to the nuclear envelope, 
whereas cytosolic calcium triggered PKC translocation to the plasma membrane.
Several growth factor receptors are known to translocate to and signal in the 
nucleus. And several transcription factors—targets of signal transduction pathways—
rely on calcium as one of their stimulatory inputs. As yet there is no obvious candidate 
pathway that combines both of these characteristics. But, if such a pathway is identified, 
two important factors—the site of calcium release and the proximity of target genes 
to this site—may help control the strength of the pathway’s output. 
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A graveyard for mRNA
 
nother day, another organelle. 
Cytoplasmic foci of various mRNA 
processing enzymes have now been 
confirmed by Ujwal Sheth and Roy 
Parker (University of Arizona, Tucson, 
AZ) as functional sites for degrading 
mRNA. But that confirmation has led 
to a host of questions about the origins 
and range of functions of these processing 
bodies (P bodies).
Sheth and Parker found that mRNA 
decapping enzymes, activators of 
decapping, and an mRNA nuclease all 
clustered in two to three P bodies per 
budding yeast cell. The P bodies melted 
away when mRNA turnover was inhibited 
before decapping (by inhibiting deadenyl-
ation), but proliferated when the inhibition 
was at or after the decapping step. Finally, 
a decay intermediate was localized to 
P bodies.
A
 
The range of reactions occurring in the 
P bodies remains to be explored, as does 
the significance of the structure. 
“Whether the [degradation] biochemistry 
requires the macroscopic environment 
[of the P body] or can occur in a dispersed 
fashion is not known,” says Parker.
A full understanding of P body control 
is also hampered by the field’s poor grip 
on what controls the switches between 
different mRNA states: from active trans-
lation to storage or destruction. At least 
one factor implicated in storage is found 
in the P bodies, so these bodies may do 
double duty in storage and destruction. 
At the very least, says Parker, the P bodies 
sequester mRNAs that are being degraded, 
so they do not compete for factors with 
mRNAs that are being actively translated. 
Determining how much additional regu-
lation is present is work for the future.
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P bodies proliferate when mRNA degra-
dation is blocked (right).
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Metastasizing in search of oxygen
 
etastatic growth can start when suffocating tumor cells go hunting for 
oxygen, according to a report from Selma Pennacchietti, Paolo Michieli, 
Paolo Comoglio, and colleagues (University of Torino, Torino, Italy).
The response appears to be part of a normal program used to create and 
maintain organs—a process that uses oxygen gradients as one guiding principle. 
“Mother Nature has given us the invasion program not to promote metastasis 
but to promote sprouting and branching of epithelial tubes,” says Comoglio.
In hypoxic tumor cells, his team found that binding of hypoxia inducible 
factor-1 (HIF-1) to two sites in the 
 
met
 
 promoter-induced expression of the 
Met tyrosine kinase receptor. This newly abundant Met, after the binding of 
ubiquitous hepatocyte growth factor (HGF, or scatter factor-1), activates an 
invasive migration program.
They found that Met levels were 
dramatically increased in the hypoxic 
areas of tumors, and that high levels of 
Met were both necessary for hypoxia-
induced branching morphogenesis and 
sufficient to induce branching morpho-
genesis in normoxic conditions.
Previous workers have stressed that 
hypoxia induces angiogenesis and 
apoptosis resistance. But the new work suggests that treatment with anti-
angiogenic agents is too simplistic. These drugs increase hypoxia in a 
tumor, and may thus promote metastasis. A combination therapy that 
attacks both angiogenic and metastatic pathways may have a better chance 
of success.
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The proinvasive effect of HGF (left) 
is amplified by hypoxia (right).
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